Angiotensin-converting enzyme inhibitors in heart failure: Physicians' prescribing behavior

Journal of Cardiac Failure

Volumn 3, Issue 4, 1997, Pages 295-302

  Ferreira, A ^a   Bettencourt, P ^a   Cortez, M ^a   Araujo J P ^a   Cerqueira Gomes, M ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Angiotensin converting enzyme inhibitors; Clinical practice; Heart failure

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DRUG UTILIZATION; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; REGRESSION ANALYSIS;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG UTILIZATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; REGRESSION ANALYSIS; VENTRICULAR FUNCTION, LEFT;

EID: 0031307391     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(97)90029-4     Document Type: Article

References (37)

1. Captopril Multicenter Research Group: A placebo-controlled trial of refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-763
2. Packer M, Lee WH, Yushak M, Medina N: Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847-853
3. Kjekshus J, Swedberg K: Tolerability of enalapril in congestive heart failure. Am J Cardiol 1988;62:67A-72A
4. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435
5. SOLVD Investigators: Effect of enalapril on survival of patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
6. Cohn JN, Johnson G, Zieshe S, Francis G, Tritsani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine-isosorbide in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
7. Rogers WG, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT: Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1994;23:393-400
8. Paul SD, Kuntz KM, Eagle KA, Weinstein NC: Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143-1149
9. Hart W, Rhodes G, McMurray JJV: The cost effectiveness of enalapril in the treatment of chronic heart failure. Br J Med Econ 1993;6:91-98
10. Davie AP, McMurray JJV: ACE inhibitors and healthcare economics. Coronary Artery Dis 1995;6:315-319
11. Bourassa MG, Gurné O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S, for the Studies of Left Ventricular Dysfunction (SOLVD) Investigators: Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22(suppl. A):I4A-9A
12. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-S112
13. Rajfer SI: Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993;22(suppl. A):198A-200A
14. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL: Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-838
15. Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA: An analysis of physicians' reasons for prescribing longterm digitalis therapy in outpatients. J Chron Dis 1985; 38:733-739
16. Cody RJ: The need for a sodium retention score in clinical trials of heart failure. Clin Pharmacol Ther 1993;54: 7-10
17. SPSS for Windows users' guide SPSS, Norusis, NJ, 1993
18. Ferreira A, Fernando PM, Cortez M, Capucho R, Brandão F, Cerqueira-Gomes M: Epidemiologic aspects of congestive heart failure: retrospective analysis of 2561 hospital admissions. Rev Port Cardiol 1996;15:395-410
19. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677
20. GISSI-3: Effects of lisinopril and transdermal glyceril trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122
21. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685
22. Ambrosioni E, Borghi C, Magnant B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators: The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality after anterior myocardial infarction. N Engl J Med 1995;332: 80-85
23. Fernando PB, Ferreira A, Dias P, Moura M, Cortez M, Capucho R, Maciel MJ, Brandão F, Cerqueira-Gomes M: Pharmacological therapy of acute myocardial infarction: from large trials to clinical practice in a central hospital. Rev Port Cardiol 1996;15:617-630
24. Mathiesen ER, Hommel E, Giese J, Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. Br Med J 1991;303:81-87
25. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462
26. Viberti GC, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with IDDM and microalbuminuria. JAMA 1994;271:275-279
27. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-581
28. Suki WN: Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med 1989;149:669-673
29. Shah N, Edep M, Massie BM: Differences between cardiologists and heart failure specialists in the management of congestive heart failure. Circulation 1995;92(suppl. 8): I-666
30. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;93:1849-1865
31. Weber KT, Villareal D: Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71: 3A-11A
32. Wester PO, Dyckner T: Intracellular electrolytes in cardiac failure. Acta Med Scand 1986;707:33-36
33. Eisenberg MJ: Magnesium deficiency and sudden death. Am Heart J 1992;124:544-549
34. Barr CS, Hanson J, Kennedy N, Lang CC, Struthers AD: The effect of a mineralcorticoid antagonist on myocardial mIBG uptake in congestive heart failure. Circulation 1993;88:I-256
35. Borghi C, Boshi S, Ambrosinoni E, Melandri G, Branzi A, Magnani B: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-45
36. Pouleur H, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Rosseau FM: Progression of left ventricular dysfunction during enalapril therapy: relation with neuro-hormonal reactivation. Circulation 1993;88:I-293
37. Pitt B, Dickstein K, Benedict CR, Pacher R, Willenheimer R, Murali S, Dunlay MC, Chang PI, Grossman W for Randomized Angiotensin Receptor Antagonist-ACE Inhibitor Study (RAAS) Investigators: The randomized angiotensin receptor antagonist-ACE inhibitor study (RAAS): pilot study. Circulation 1996;94:I-428